AU2019309757A1 - Tumor reduction formulations and methods of use thereof - Google Patents

Tumor reduction formulations and methods of use thereof Download PDF

Info

Publication number
AU2019309757A1
AU2019309757A1 AU2019309757A AU2019309757A AU2019309757A1 AU 2019309757 A1 AU2019309757 A1 AU 2019309757A1 AU 2019309757 A AU2019309757 A AU 2019309757A AU 2019309757 A AU2019309757 A AU 2019309757A AU 2019309757 A1 AU2019309757 A1 AU 2019309757A1
Authority
AU
Australia
Prior art keywords
composition
tumor
acid
agent
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019309757A
Other languages
English (en)
Inventor
Steven Hoffman
John Rothman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tyme Inc
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of AU2019309757A1 publication Critical patent/AU2019309757A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2019309757A 2018-07-09 2019-07-02 Tumor reduction formulations and methods of use thereof Abandoned AU2019309757A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695613P 2018-07-09 2018-07-09
US62/695,613 2018-07-09
PCT/US2019/040264 WO2020023191A1 (en) 2018-07-09 2019-07-02 Tumor reduction formulations and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2019309757A1 true AU2019309757A1 (en) 2021-03-04

Family

ID=75267393

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019309757A Abandoned AU2019309757A1 (en) 2018-07-09 2019-07-02 Tumor reduction formulations and methods of use thereof

Country Status (11)

Country Link
EP (1) EP3820482A4 (https=)
JP (1) JP2021530482A (https=)
KR (1) KR20220098082A (https=)
CN (1) CN112584841A (https=)
AU (1) AU2019309757A1 (https=)
BR (1) BR112021000279A8 (https=)
CA (1) CA3105717A1 (https=)
EA (1) EA202190201A1 (https=)
IL (1) IL280000A (https=)
PH (1) PH12021550033A1 (https=)
WO (1) WO2020023191A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220152051A1 (en) * 2019-03-15 2022-05-19 Dalian University Application of glycocholic acid in preparation of antitumor drugs
WO2020232227A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
US20210169903A1 (en) * 2019-12-09 2021-06-10 Tyme, Inc. Pharmaceutical compositions and methods
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050202094A1 (en) * 2004-01-29 2005-09-15 Werling Jane O. Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
WO2006099685A1 (en) * 2005-03-24 2006-09-28 Medical Therapies Limited Method for the prophylaxis or treatment of carcinomas
CN101023940A (zh) * 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
WO2016007741A1 (en) * 2014-07-11 2016-01-14 The Regents Of The University Of California Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
US9687528B2 (en) * 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations
EP3429583A1 (en) * 2016-03-15 2019-01-23 Tyme, Inc. Pharmaceutical compositions for the treatment of cancer

Also Published As

Publication number Publication date
CA3105717A1 (en) 2020-01-30
IL280000A (en) 2021-03-01
EA202190201A1 (ru) 2021-04-09
BR112021000279A2 (pt) 2021-04-06
EP3820482A4 (en) 2022-03-23
WO2020023191A1 (en) 2020-01-30
KR20220098082A (ko) 2022-07-11
PH12021550033A1 (en) 2021-09-20
JP2021530482A (ja) 2021-11-11
CN112584841A (zh) 2021-03-30
BR112021000279A8 (pt) 2021-04-20
CN112584841A8 (zh) 2021-06-18
EP3820482A1 (en) 2021-05-19

Similar Documents

Publication Publication Date Title
EP3820482A1 (en) Tumor reduction formulations and methods of use thereof
EP2970280B1 (en) Methods for treating inflammation, autoimmune disorders and pain
Barbul et al. Wound healing and thymotropic effects of arginine: a pituitary mechanism of action
KR102061486B1 (ko) 에키노칸딘 계열의 화합물에 대한 투여 용법
JP5919597B2 (ja) デオキシコール酸およびその塩類の製剤
AU2017238817A1 (en) Conjugate vaccine targeting a disease-causing biological protein
US20210275467A1 (en) Tumor reduction formulations and methods of use thereof
JP6509827B2 (ja) 転移を減少させるまたは阻止するための組成物および方法
CN101896190A (zh) 用α胸腺肽和抗细胞毒性T淋巴细胞相关抗原4(CTLA4)的抗体的组合治疗黑素瘤
KR102177304B1 (ko) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
JP2006505564A (ja) Ｓａｒｍによる高齢男性のアンドロゲン減少に関連する病気の治療
TWI510243B (zh) 用於治療膀胱癌的組成物及方法
US20200397881A1 (en) Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy
JP4807972B2 (ja) 皮膚外用剤
CN110402142A (zh) 含局麻药的酸性乳液组合物
CN117651567A (zh) 包含glp-1类似物的口服制剂的组合物
HU230920B1 (hu) Depresszió kezelésére szolgáló androgén gyógyászati készítmények
US20070207965A1 (en) Method for the treatment of skin fibrosis and suitable compositions for such treatment
EP4065108B1 (en) Formulations of terameprocol and temozolomide and their use in stimulation of humoral immunity in tumors
WO2017120568A1 (en) Apoe mimetic peptide compositions
AU2017414006A1 (en) Use of polypeptide compound in treatment of acute pancreatitis
Amoroso et al. Megestrol acetate plus alpha 2a interferon as second line therapy for postmenopausal patients with advanced breast cancer: results of a multicentric phase II trial
CN118317780A (zh) 脂肪肝和非酒精性脂肪肝炎的治疗药

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO READ 62/695,613 09 JUL 2018 US

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period